Abstract

Shivkant Patel^1*, Piyushkumar Sadhu¹, Mamta Kumari¹, Dillip Kumar Dash¹, Surabhi Jain², Ashim Kumar Sen¹

DOI : http://dx.doi.org/10.13005/ojc/390316

The second-most common reason for death globally and a significant issue for human health is cancer. The focus of the current review is to discuss cancer treatment and issues with anti-cancer medications. Nearly all cell types can develop cancer, a very varied group of approximately 200 illnesses with at least one factor in common “uncontrolled cellular development” that results in aberrant cell proliferation. In solid tumors, cancerous cells may remain localized or in situ at the location of the initial lesion, or they may become locally progressed or metastatic to distant site. Ninety percent of all cancer-related fatalities are due to by metastasis. It is the primary determinant of whether malignancy is high-risk, requiring aggressive treatment, or low-risk, curable by active surveillance, surgical removal, or adjuvant therapy. Recent advancements in computational drug discovery methodologies have not only produced important insights into the field of cancer therapy but have also had a significant and impact on the development of novel anticancer medications. Within the scope of this review, we investigated potential therapeutic targets for anti-cancer drugs.

Anti-cancer agents; Aromatase Inhibitors; Cancer; Aromatase Inhibitors; HIF inhibitors; MAPK Inhibitors; PLK1 Inhibitors

[ View HTML Full Text]